Govind Persad (also @govindpersad.bsky.social)

Associate prof @UofDenver @SturmCOL, teaching #healthlaw. @StanfordPhil/@StanfordLaw/@NIHBioethics alum. Mastodon:

[Zeke Emanuel @ZekeEmanuel]

Despite the efficacy of GLP-1s in treating obesity, the high cost of these drugs pose significant challenges for public health systems worldwide.

In @TheLancet, Johan Dellgren, @GovindPersad, and I look at the limitations and the promises of GLP-1s. https://t.co/WyUjWyLhOT

[AJKD @AJKDonline]

Association of Race and Ethnicity With High Longevity Deceased Donor Kidney Transplantation Under the US Kidney Allocation System

https://t.co/ChtHOJc9qO

@PeterPReese1 @MildaSaundersMD @DrMonicaPeek @GovindPersad @WF_Parker @uofcneph

[The ASCO Post @ASCOPost]

Govind Persad, JD, PhD, on Understanding the Legal and Ethical Challenges AI Poses in Oncology https://t.co/VhPPc0F1cE #oncology #AI @GovindPersad

[Leah Pierson @leah_pierson]

There are many more results in the paper, so check it out!

https://t.co/VXlUXIb9Ib

(Feel free to email/DM me if you can't access it.)

And a huge shout out to the whole VIBES team: @sophiehgibert, Leila Orszag, @_Haley_Sullivan, Rachel Fei, @GovindPersad, and @emily_a_largent.

[Leah Pierson @leah_pierson]

Our article, Bioethicists Today: Results of the Views in Bioethics Survey (VIBeS), is now out in AJOB!

We surveyed 824 US bioethicists on:

(1) Major issues in bioethics, like medical aid in dying, paying organ donors, abortion, and many others

(2) Their backgrounds

🧵

[Govind Persad (also @govindpersad.bsky.social) @GovindPersad]

With @ZekeEmanuel @matthew_s_mccoy & Johan Dellgren, drawing on work presented @BCEPShealth
https://t.co/CR3JlacMS5

[Jessamy Bagenal BSc, MBBS, MRCS, MPH, FRSPH 🖌🗣🌕 @JessamyBagenal]

Using GLP-1 scarcity as a working example. Prof Ezekiel Emmanuel says allocation has been done in many countries without any thought to ethics. But if you’re 20 + have a BMI of >45 you may lose up-to 13 years of your life: if you are 70 + have a BMI >45 it is only 3. So what is fair? @BCEPShealth

[Govind Persad (also @govindpersad.bsky.social) @GovindPersad]

'Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor Agonists' is out in @NEJM (ungated)
https://t.co/04kMmEIB1O

We propose a framework to guide goverments, professional societies, & docs in allocation choices about drugs like semaglutide (#Ozempic/#Wegovy) when demand > supply

[Anand Parekh, MD, MPH @AParekh_UM]

"Coverage for weight-loss drugs could reduce obesity immediately while less consumption of harmful foods could help prevent it. Fewer people would need expensive treatments like Wegovy in the longer term."

@GovindPersad & @ZekeEmanuel via @WSJopinion

https://t.co/T38umnaAO4

[Zeke Emanuel @ZekeEmanuel]

In my latest for @WSJ, @GovindPersad & I argue that North Carolina’s decision to deny coverage for GLP-1 drugs like #ozempic for individuals with obesity is both unethical and short-sighted. Read below ⬇️ 1/4
https://t.co/nTJWnBE1ns

[Jane Liebschutz (she/her) @liebschutz.bsky.social @liebschutz]

For Obese Patients, Wegovy Is Worth the Cost by @GovindPersad and @ZekeEmanuel https://t.co/6WUMv4MxDG via @WSJopinion

[Govind Persad (also @govindpersad.bsky.social) @GovindPersad]

Here is another link if you have trouble accessing the op-ed https://t.co/e3mZTuSm4L

[Govind Persad (also @govindpersad.bsky.social) @GovindPersad]

North Carolina & other health systems are being unethical when they categorically refuse to cover GLP-1 receptor agonists (e.g. Ozempic, Mounjaro) for obesity. So I & @ZekeEmanuel argue in our @WSJ op-ed.

https://t.co/o3hAVkJGZR

Thread highlighting a few points 1/5

#bioethics

[Govind Persad (also @govindpersad.bsky.social) @GovindPersad]

Last, while trade-offs in drug spending are inevitable, creative use of Pigouvian taxes could lessen their sharpness

Taxing soda & other obesogenic foods could raise revenues for covering GLP-1 receptor agonists, while mitigating the need for them.

https://t.co/i0CDKT246L

[Govind Persad (also @govindpersad.bsky.social) @GovindPersad]

@CourtneyGJoslin @michlawreview Thank you!

[Govind Persad (also @govindpersad.bsky.social) @GovindPersad]

Revised draft of “Antiracist Medicine in Colorblind Courts,” forthcoming @michlawreview: https://t.co/ZarzsqZNyF

Added material on new §1981, §1557, and Equal Protection litigation against health & other programs that consider individuals’ race.

New TX & UT laws also discussed

[Govind Persad (also @govindpersad.bsky.social) @GovindPersad]

Some of the grant cases are patterned on litigation against non-health grantmakers (e.g. Atlanta's Fearless Fund) being brought by the same organization and attorneys that litigated the Harvard/UNC affirmative action cases:

https://t.co/s4DmCfkowi

[Govind Persad (also @govindpersad.bsky.social) @GovindPersad]

Litigation has targeted consideration of individuals’ race in:

-grants to health trainees
https://t.co/ilM7VPUFWj; https://t.co/NmSaZFb7zm

-physician recruitment https://t.co/vLfz7GSMJV

-medical board composition
https://t.co/3lWLJi9WwB; https://t.co/QGkrTb5jXQ